A leading automation company powering life sciences labs, has raised $40m to accelerate its rapid growth and industry presence across the US, UK and EMEA.
Intellia suggests ATTR amyloidosis gene editing treatment has over a year of durability as it gears up for PhIII
Intellia on Thursday presented new results for its gene editing treatment in 65 patients with ATTR amyloidosis — a condition in which misfolded proteins build